This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Reunion Neuroscience is an early stage pharmaceutical company developing new molecules to treat mental health conditions. The company’s team is composed of successful entrepreneurs and scientific leaders with deep experience in nearly every aspect of pharmaceutical development.
Previously a part of Field Trip Health Ltd. under the name Field Trip Discovery, Reunion is now an independent public company focused on developing therapeutics. The board unanimously approved the reorganization in April of 2022, with Field Trip Health now being renamed Reunion Neuroscience Inc.
Stock Performance
Reunion Neuroscience News 41 articles
- Reunion Neuroscience appoints Sahil Kirpekar as President and CEO
- Reunion to present full RECONNECT Phase 2 data for luvesilocin in postpartum depression
- FDA grants Breakthrough Therapy Designation to Reunion's luvesilocin (RE104) for postpartum depression
- Reunion doses first patient in REKINDLE Phase 2 trial of RE104
- Reunion Neuroscience upsizes Series A to $133 million after positive trial data
- Reunion's RE104 hits primary endpoint in Phase 2 RECONNECT postpartum-depression trial
- Reunion publishes RE104 Phase 1 data in the Journal of Clinical Psychopharmacology
- Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
- Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders
- Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
- Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference
- Reunion Neuroscience Inc. to Participate in October Investor Conferences
- Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
- Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
- Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement
- Reunion Neuroscience Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
- Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact
- Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference
- Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors
- Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
- Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
- Reunion Neuroscience Files Lawsuit Against Mindset Pharma
- Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
- Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
- Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
- Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer
- Greg Mayes, CEO of Reunion, Sits in the Investor Hotseat on January 16th
- Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
- Reunion Neuroscience Inc. Provides 2023 Corporate Update
- Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December
- Reunion Neuroscience Puts in Place At-The-Market Equity Facility
- Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results
- Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET
- Reunion Neuroscience to Present at Upcoming November Conferences
- Reunion Neuroscience Opens the Market
- Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs
- Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference
- Reunion Neuroscience Inc. Announces Executive Changes
- Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting
- Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer
Showing the 40 most recent of 41 articles.